Carbohydrate Deficient Glycoprotein Syndrome Type II

Carbohydrate-deficient glycoprotein syndrome type II is a group of rare, inherited conditions where the body has trouble finishing the “sugar decorations” that are added to many proteins. These sugar chains (called glycans) help proteins fold, travel inside cells, stick to other cells, and work correctly. In CDG-II, the early sugar chain is built, but the trimming and processing steps inside the Golgi apparatus go wrong. Because of this, many organs—especially the brain and nerves—do not work as they should. Children usually show signs in infancy or early childhood. The condition is autosomal recessive, which means a child needs a changed (pathogenic) copy of the gene from each parent. PubMed+1

The name “type II” comes from older testing patterns on a blood protein called transferrin. In CDG-II, transferrin shows an abnormal pattern because its attached sugars are processed incorrectly. Doctors still use modern transferrin tests and gene testing to help confirm CDG today. ScienceDirect+1

---

Other names

• CDG-II (congenital disorder of glycosylation, type II)

• Carbohydrate-deficient glycoprotein syndrome type II (older name)

• Subtype names based on the gene, for example MGAT2-CDG (CDG-IIa), MOGS-CDG (CDG-IIb), SLC35C1-CDG (CDG-IIc / LAD-II), and several COG-CDG subtypes (COG1, COG4, COG5, COG6, COG7, COG8). Frontiers+3rarediseases.org+3rarediseases.org+3

---

Types

“Type II” is an umbrella. Below are well-known CDG-II subtypes named by gene:

• MGAT2-CDG (CDG-IIa): a processing enzyme defect (N-acetylglucosaminyltransferase II). Orpha.net

• MOGS-CDG (CDG-IIb): glucosidase I defect that blocks early trimming in the ER/Golgi. PubMed+1

• SLC35C1-CDG (CDG-IIc; LAD-II): a GDP-fucose transporter defect that impairs fucosylation; causes immune and growth problems. CDG Hub+2Frontiers in Glycosylation+2

• COG-CDG (e.g., COG1/4/5/6/7/8): defects in the Conserved Oligomeric Golgi complex, a trafficking machine needed for proper glycosylation. Frontiers+1

(There are many more genes in CDG-II, but these illustrate the idea that “type II” means processing/trafficking problems rather than the early assembly problems seen in “type I”.) Wikipedia

---

Causes

Each “cause” is a gene problem that disrupts sugar-chain processing/transport. A child usually inherits one changed gene from each parent.

1. MGAT2 (MGAT2-CDG / IIa): The enzyme that adds a key branch to the sugar chain is missing or weak. Proteins keep an immature pattern and do not work well. Typical signs include facial differences, seizures, developmental delay, and bleeding tendency. Orpha.net

2. MOGS (MOGS-CDG / IIb): The first trimming step (glucosidase I) cannot remove glucose from the new glycan. This traps proteins in a mis-processed state and can cause severe infant disease. PubMed

3. SLC35C1 (CDG-IIc / LAD-II): The cell cannot import GDP-fucose into the Golgi, so fucose is not added to glycans. White blood cells then lack the “homing” sugar (sialyl-Lewis X), leading to infections, high white counts, poor growth, and developmental issues. CDG Hub+1

4. B4GALT1 (CDG-IId): A galactosyltransferase problem that reduces galactose addition to glycans, disturbing many glycoproteins. (Subtype listed among type II in medical references.) Wikipedia

5. SLC35A1 (CDG-IIf): CMP-sialic acid transporter defect. Sialic acid cannot reach the Golgi lumen, so end-stage “caps” on glycans are missing, affecting cell signaling and stability. Wikipedia

6. COG1 (CDG-IIg): Part of the COG complex that maintains Golgi trafficking; defects disturb both N- and O-glycosylation and cause multi-system disease. BioMed Central

7. COG8 (CDG-IIh): Another COG subunit; patients show growth and neurological problems due to widespread glycosylation failure. Oxford Academic

8. COG5 (CDG-IIi): Disrupted vesicle tethering in Golgi leads to mis-localization of glycosylation enzymes and abnormal glycans. Frontiers

9. COG4 (CDG-IIj): Similar Golgi trafficking defect; reported patients help prove how Golgi transport controls glycan processing. PMC

10. COG6 (often termed CDG-IIL): COG subunit loss causes severe multi-system features and abnormal N- and O-glycans. ScienceDirect

11. COG7 (CDG-IIe): Loss of this COG subunit is often severe and can be life-threatening in infancy. Wikipedia

12. MAN1B1: Trimming mannosidase defect; may present with developmental delay and facial features. (Recognized among type II processing defects.) Wikipedia

13. ATP6V0A2: A vesicle acidification defect causing impaired glycosylation; known for cutis laxa with CDG features. Wikipedia

14. ST3GAL3: A sialyltransferase defect that affects brain development and can cause intellectual disability. Wikipedia

15. GALNT2 (CDG2T): An initiating O-GalNAc transferase affecting O-glycans; included among CDG-II subtypes in curated lists. Wikipedia

16. COG complex (general point): Any subunit mutation can produce CDG-II with microcephaly, hypotonia, bleeding issues, and intellectual disability because Golgi trafficking fails. Frontiers

17. Multiple-pathway transport defects (category): When the cell cannot move activated sugars (like fucose or sialic acid) into the Golgi, many glycans are under-finished. SLC35 family genes are key examples. CDG Hub

18. Early ER trimming/quality control defects (category): Problems with the first glucose trimming steps (like MOGS) interrupt protein folding cycles and downstream processing. PubMed

19. Glycosylation enzyme mis-localization (category): When Golgi transport/tethering is broken (COG defects), enzymes sit in the wrong place, so the sugar chain cannot be finished correctly. PNAS

20. Broad CDG spectrum (context): CDG-II sits within >130 CDG conditions overall; many rare genes keep being discovered, so gene panels are used. invitae.com

---

Symptoms and signs

1. Global developmental delay: slow motor and language milestones are common because brain development is affected by many faulty glycoproteins. NCBI

2. Low muscle tone (hypotonia): weak muscle tone in infancy makes feeding and movement harder. NCBI

3. Seizures: abnormal brain electrical activity happens in many subtypes and needs neurologic care. Orpha.net

4. Feeding problems and poor weight gain: coordination and GI issues lead to failure to thrive in some infants. NCBI

5. Vision problems: strabismus or other visual disturbance can occur. NCBI

6. Hearing loss: sensorineural hearing loss is reported in several CDG forms. NCBI

7. Facial features: some subtypes have recognizable facial differences (for example MGAT2-CDG). Orpha.net

8. Bleeding tendency or easy bruising: poor platelet function can occur because platelet glycoproteins are under-glycosylated. Orpha.net

9. Liver involvement: abnormal liver enzymes or function can be seen because many liver proteins are glycoproteins. heftpathology.com

10. Growth problems: short stature or poor linear growth may be present. CDG Hub

11. Frequent infections (especially in SLC35C1-CDG / LAD-II): white blood cells cannot home to infection sites normally, so infections and very high neutrophil counts can occur. NCBI

12. Cognitive impairment: learning difficulties range from mild to severe depending on the subtype. Frontiers

13. Movement problems: ataxia or poor coordination may be present, although early reports noted less cerebellar hypoplasia in “type II” than in “type I”. PubMed

14. Microcephaly (in several COG defects): the head size can be smaller due to brain growth problems. Frontiers

15. Skeletal or skin findings (in selected subtypes): for example, cutis laxa with ATP6V0A2-CDG. Wikipedia

(Every child is different. Not all features appear in every subtype.)

---

Diagnostic tests

A) Physical examination

1. General growth check: measuring weight, length/height, and head size helps show global growth issues that often appear in CDG-II. Doctors also look for fat distribution and muscle tone. NCBI

2. Neurologic exam: tone, reflexes, eye movements, coordination, and developmental skills are assessed because the nervous system is commonly affected. NCBI

3. Dysmorphology assessment: a genetics-trained clinician looks for facial patterns and other features (for example, those seen in MGAT2-CDG) that can guide testing. Orpha.net

4. Infection history and exam: in SLC35C1-CDG/LAD-II, doctors look for recurrent infections, poor wound healing, and very high white counts despite infection signs. NCBI

B) “Manual” bedside/clinic tests

5. Developmental screening tools: standardized checks for motor, language, and social skills document delays and help plan therapy. These are practical bedside assessments supported by the known neurodevelopmental impact of CDG. NCBI

6. Ophthalmology examination: eye alignment and retinal exam identify strabismus or other visual problems common in CDG. NCBI

7. Audiology testing (behavioral and OAE/ABR screening): early detection of hearing loss guides timely intervention. NCBI

8. Bleeding assessment tools: structured bleeding histories (easy bruising, nosebleeds) correlate with platelet dysfunction noted in some subtypes such as MGAT2-CDG. Orpha.net

C) Laboratory and pathological tests

9. Transferrin isoelectric focusing (IEF): the classic screen for CDG. It separates transferrin glycoforms; abnormal patterns suggest type I vs type II defects and prompt gene testing. ScienceDirect

10. Mass spectrometry of transferrin glycoforms (LC-MS): a sensitive, modern method that defines abnormal glycoforms precisely and speeds diagnosis. Often used with or instead of IEF. Analytical Science Journals+1

11. Serum N-glycan/O-glycan profiling: broader glycan analysis on serum proteins can reveal the specific processing failure seen in CDG-II. ScienceDirect

12. Genetic testing—targeted CDG panel or exome/genome: confirms the exact gene (for example MGAT2, MOGS, SLC35C1, COG genes). Panels cover many CDG genes at once and are standard of care when biochemistry suggests CDG. invitae.com

13. Coagulation studies and platelet function: many glycoproteins drive clotting and platelet adhesion; abnormal results support a systemic glycosylation problem. heftpathology.com

14. Liver function tests: elevated transaminases or synthetic function changes (albumin, clotting factors) can reflect hepatic involvement in CDG. heftpathology.com

15. Immune cell glycan markers in LAD-II: flow cytometry can show loss of sialyl-Lewis X (CD15s) on neutrophils in SLC35C1-CDG, matching the fucosylation defect. NCBI

16. Confirmatory enzyme/transport assays (specialized labs): in select centers, functional assays (e.g., glucosidase I activity for MOGS) or substrate transport tests can support the gene finding. PubMed

D) Electrodiagnostic tests

17. EEG (electroencephalogram): checks for seizure activity and background abnormalities that fit the neurologic phenotype seen in many CDG-II subtypes. NCBI

18. Nerve conduction studies/EMG (when indicated): evaluate weakness or tone problems. Some early “type II” reports noted less peripheral neuropathy than “type I,” but testing is still used case-by-case. PubMed

E) Imaging tests

19. Brain MRI: looks for structural changes (for example microcephaly, cerebellar findings, or other developmental abnormalities), which vary by subtype and can be notable in COG defects. Frontiers

20. Targeted organ imaging: echocardiogram, abdominal ultrasound, or skeletal imaging if symptoms suggest involvement; these help manage complications in multi-system disease. (Use guided by clinical features described for CDG.)

Non-pharmacological treatments (therapies and others)

1. Nutrition therapy: high-calorie, balanced diet; feeding support to prevent malnutrition and support growth. Mechanism: improves energy supply and healing.

2. Feeding therapy/texture modification: safer swallowing; reduces aspiration. Purpose: protect lungs and improve intake.

3. NG/PEG feeding when needed: ensures reliable nutrition if oral intake is unsafe or inadequate. Mechanism: bypasses weak swallow/poor appetite.

4. Physical therapy: builds strength, posture, and motor skills; reduces contractures. Mechanism: neuro-motor training and muscle conditioning.

5. Occupational therapy: fine-motor skills, daily living tasks, adaptive equipment. Mechanism: task-specific training and environmental modification.

6. Speech-language therapy: speech clarity and safe swallow; alternative communication tools if needed.

7. Early-intervention/educational support: individualized learning plan; simple routines; visual schedules. Mechanism: repetition and structured teaching.

8. Vision care: glasses, patching, and vision therapy for strabismus or tracking problems.

9. Hearing support: hearing aids or FM systems to boost language and learning.

10. Orthotics and bracing: improves gait and prevents deformities (AFOs, spinal braces).

11. Positioning and mobility devices: strollers, walkers, wheelchairs for safe mobility and participation.

12. Behavioral and psychological support: coping skills for child and family; addresses anxiety/depression.

13. Sleep hygiene program: regular schedule, calming routine; improves daytime function.

14. Dental care plan: fluoride, frequent checks; some CDG patients have enamel issues or feeding-related risk.

15. Vaccination and infection-prevention coaching: hand hygiene, prompt care for fevers; critical in immune-affected subtypes (e.g., LAD II). Mechanism: reduces infection risk. PMC

16. Coagulation safety plan: avoid unnecessary trauma; medic alert; procedure planning given clotting abnormalities. NCBI

17. Liver-care lifestyle: avoid unnecessary alcohol in adults, cautious use of hepatotoxic meds; nutrition for cholestasis. NCBI

18. Multidisciplinary clinic: coordinated visits (genetics, neurology, hepatology, rehab, nutrition). Mechanism: faster problem-solving and continuity.

19. Genetic counseling for the family: explains inheritance, recurrence risk, and options for future pregnancies. NCBI

20. Community and social-work support: services, respite care, and school accommodations.

---

Drug treatments

Important: These are general options; the exact plan must be individualized by a specialist, especially where liver, coagulation, or electrolytes are involved.

Targeted “substrate/ion” therapies (gene-specific):

1. Oral D-galactose in SLC35A2-CDG: improves glycosylation and clinical scores; typical research protocols use divided daily dosing, often titrated up to ~0.5–1 g/kg/day (max ~50 g/day) in other galactose-responsive CDGs; dosing for SLC35A2 is individualized in clinic. Monitor glucose and labs. Mechanism: boosts UDP-galactose in the Golgi. PMC+1

2. Oral L-fucose in SLC35C1-CDG (LAD II): can improve psychomotor development and infection risk in responders; published doses vary widely (~25–2000 mg/kg/day in divided doses). Requires close monitoring; not all patients respond. Mechanism: activates salvage pathway to make GDP-fucose. PMC+2Nature+2

3. Oral manganese in SLC39A8-CDG (and case-based use with TMEM165-CDG under expert care): improves enzyme function and seizures/motor features in reports; dosing is specialist-guided with serum Mn and safety monitoring due to neurotoxicity risk. Mechanism: restores Mn²⁺ cofactor for glycosyltransferases. GIM Journal+2ScienceDirect+2

4. D-galactose ± manganese in TMEM165-CDG (case report): combined therapy improved biochemical profiles; this is emerging and strictly specialist-supervised. PubMed+1

5. D-galactose in PGM1-CDG (a different CDG that is galactose-responsive): included here to illustrate principle; not a CDG-II subtype but often discussed in glycosylation therapy literature. PMC+1

Symptom-directed medicines (commonly used):

6. Antiseizure medicines (e.g., levetiracetam; others as needed). Purpose: seizure control; Mechanism: neuronal excitability modulation. Use liver-safe choices if hepatic disease. NCBI

7. Acetazolamide for episodes of ataxia in some CDGs (case-based). Purpose: reduce episodic ataxia; Mechanism: carbonic anhydrase inhibition alters neuronal excitability. (Evidence is limited; specialist trial.) PMC

8. Baclofen or tizanidine for troublesome spasticity. Purpose: ease stiffness; Mechanism: GABA-B agonism (baclofen) or α2-agonism (tizanidine).

9. Clonazepam for myoclonus or sleep-related movement disorders.

10. Proton-pump inhibitor for significant reflux. Purpose: reduce acid injury; Mechanism: blocks gastric acid pumps.

11. Antiemetics/prokinetics when severe vomiting affects hydration and growth.

12. Pancreatic enzyme replacement if documented exocrine pancreatic insufficiency (not universal).

13. Ursodeoxycholic acid for cholestasis in select patients. Purpose: improve bile flow; Mechanism: hydrophilic bile acid replacement. NCBI

14. Vitamin K (and other fat-soluble vitamins) in cholestasis or coagulopathy; antithrombin or factor concentrates for procedures when levels are very low. Purpose: safer clotting. NCBI

15. Thyroid hormone replacement when hypothyroidism is confirmed.

16. Growth hormone only if true GH deficiency is proven by an endocrinologist.

17. Antibiotics for bacterial infections; prophylaxis may be considered by immunology in frequent infections (e.g., LAD II). PMC

18. IVIG may be considered in selected immune-related complications at an immunologist’s discretion.

19. Pain medicines (acetaminophen first-line; careful with NSAIDs if liver issues).

20. Stool softeners/laxatives for constipation to improve comfort and feeding.

Notes on dosing: many of the supportive medicines follow standard pediatric/adult dosing. For D-galactose, L-fucose, and manganese, dosing is specialist-set with lab monitoring and safety checks; published research reports show ranges rather than one universal dose. Do not start these without a metabolic specialist. ScienceDirect+2PMC+2

---

Dietary molecular supplements

1. D-galactose (specialist-directed; subtype-specific): adds substrate for galactosylation. (See above.) PMC

2. L-fucose (specialist-directed; SLC35C1/LAD II; selected FUT-pathway CDGs): fuels fucose salvage to GDP-fucose. PMC

3. Manganese (specialist-directed; SLC39A8/TMEM165 cases): restores metal cofactor for enzymes; needs tight monitoring. GIM Journal

4. Fat-soluble vitamins (A, D, E, K) during cholestasis: replaces poorly absorbed vitamins to protect vision, bone, nerves, and clotting. NCBI

5. Omega-3 fatty acids: general anti-inflammatory support; may help nutrition and cardiovascular health.

6. Carnitine if low: supports fatty-acid energy use; helps reduce fatigue.

7. Multivitamin with minerals (iron, zinc as needed): supports growth; corrects deficits from feeding issues.

8. Calcium plus vitamin D: bone health, especially with limited mobility.

9. Medium-chain triglyceride (MCT) oil: extra calories for growth when intake is low or absorption is poor.

10. Probiotics (case-by-case): gut comfort and stool regularity; choose pediatric-appropriate strains.

(Supplements beyond items 1–3 are supportive rather than disease-modifying. Always coordinate with the care team.)

---

Regenerative / stem-cell drugs

There are no approved “stem-cell drugs” or general “immunity booster drugs” proven to correct CDG-II. What exists are case-specific, specialist treatments and procedures:

1. Oral L-fucose in LAD II (SLC35C1-CDG) can functionally improve leukocyte adhesion and reduce infections in responders. This is not an immune booster per se; it fixes a specific sugar-transport defect. PMC

2. Manganese therapy in SLC39A8-CDG can improve neurologic and enzymatic functions by restoring a missing cofactor. GIM Journal

3. Combined D-galactose + manganese has been reported in TMEM165-CDG under tight supervision. PubMed

4. IVIG or granulocyte-stimulating strategies may be used by immunologists for recurrent infections or neutrophil issues in selected patients—not disease-curing.

5. Hematopoietic stem cell transplantation (HSCT) is not standard for CDG-II but has been considered in some severe primary immunodeficiencies; for LAD II, oral fucose is the primary therapy, and HSCT would be exceptional. Karger

6. Gene-targeted therapies are experimental; families can ask about clinical trials run by CDG research networks.

(If anyone proposes “stem-cell injections” outside a trial, be cautious; this is not an approved or proven CDG-II treatment.)

---

Surgeries

1. Gastrostomy (PEG) placement: if long-term tube feeding is required to guarantee safe, steady nutrition.

2. Anti-reflux surgery (fundoplication): for severe reflux not controlled by medicine, to protect lungs and improve feeding.

3. Strabismus surgery: improves eye alignment and visual development if patching/therapy are not enough.

4. Orthopedic procedures (tendon lengthening, scoliosis correction): reduce deformity, improve function and comfort.

5. Liver transplantation: rare and only in severe, end-stage liver disease after multidisciplinary assessment; it does not fix the genetic cause but may address life-threatening liver failure.

---

Preventions

1. Genetic counseling for parents and adult patients (autosomal recessive in most CDG-II). NCBI

2. Carrier testing and prenatal options for future pregnancies when a family variant is known. NCBI

3. Vaccinations on schedule (adjusted only if an immunologist advises).

4. Hand hygiene and early treatment of fevers to prevent complications from infections.

5. Nutrition plan to prevent failure to thrive.

6. Physical therapy program to prevent contractures and deconditioning.

7. Coagulation safety plan to prevent bleeding during procedures. NCBI

8. Liver-friendly lifestyle and medication review to prevent avoidable injury. NCBI

9. Dental prevention (fluoride, regular cleanings) to avoid caries and feeding-related dental erosion.

10. Care coordination to prevent missed follow-ups and medication errors.

---

When to see doctors (red flags)

• Any first seizure, repeated vomiting, poor feeding, or dehydration.

• Jaundice, very pale stools, or easy bruising/bleeding. NCBI

• High fever or signs of serious infection, especially in LAD II. PMC

• Breathing difficulties, choking with feeds, or poor weight gain.

• New weakness, regression of skills, or severe balance problems.

• Before any surgery or dental procedure (to plan coagulation support). NCBI

---

What to eat and what to avoid

• Eat: a balanced diet with enough calories and protein; plenty of fruits/vegetables; whole grains; healthy fats. Use energy-dense add-ons (oils, nut butters, MCT oil) if weight gain is hard.

• If your specialist prescribes it: D-galactose, L-fucose, or manganese—take only under medical supervision with lab monitoring. PMC+2PMC+2

• If cholestasis is present: support fat-soluble vitamins (A, D, E, K) and follow the liver team’s diet advice. NCBI

• Avoid: skipping meals in small children with poor reserves; alcohol in older teens/adults with liver disease; and unapproved “stem-cell” products or supplements claiming to cure CDG.

---

FAQs

1) Is CDG-II one disease?
No. It’s a group of genetic conditions that share a similar lab pattern (type II transferrin) because they affect glycan processing in the Golgi. PMC

2) How is it diagnosed?
By transferrin glycoform testing and genetic testing to find the exact gene. PMC+1

3) Can CDG-II be cured?
There is currently no universal cure, but some subtypes have targeted treatments (galactose, fucose, manganese) that can improve symptoms and lab markers. PMC+2PMC+2

4) Why do symptoms vary so much?
Different genes, different tissues, and different enzyme roles lead to different patterns of organ involvement. NCBI

5) What is the type II transferrin pattern?
A blood test showing fewer sialic-acid “caps” on transferrin, consistent with processing defects. PMC

6) Is the brain affected?
Often yes—development, tone, coordination, and seizures can be involved. NCBI

7) Are infections a big problem?
In SLC35C1/LAD II, yes, because white blood cells cannot stick and exit blood vessels well; some patients respond to oral fucose. PMC

8) Can manganese help everyone?
No. It is specific for certain subtypes (notably SLC39A8-CDG, sometimes TMEM165-CDG) and must be supervised due to toxicity risk. GIM Journal+1

9) Is galactose therapy safe?
It can be helpful in selected subtypes (SLC35A2-CDG; PGM1-CDG) and is monitored for side effects like hyperglycemia; dosing is individualized. PMC+1

10) What about mannose?
Mannose works for MPI-CDG (a type I CDG), not for CDG-II in general. It’s a good example that therapy depends on the gene. PubMed+1

11) Does every child need a feeding tube?
No. It’s used only when safe oral feeding and growth are not possible.

12) Can liver problems get serious?
They can, and bleeding/clotting issues need careful planning before procedures. Rarely, liver transplant is considered for end-stage disease. NCBI

13) Will my child walk or talk?
Many children improve with therapy; outcomes vary by subtype and severity.

14) Should we join a registry or trial?
Yes—CDG registries and trials can provide access to expertise and emerging treatments.

15) What’s the most important next step after diagnosis?
Set up multidisciplinary care (genetics, neurology, rehab, nutrition, hepatology), and ask if your child’s subtype has targeted options like galactose, fucose, or manganese. NCBI

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 12, 2025.